Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Michael Torsten Meister"'
Autor:
Lieke M. J. van Zogchel, Nathalie S. M. Lak, Nina U. Gelineau, Irina Sergeeva, Ellen Stelloo, Joost Swennenhuis, Harma Feitsma, Max van Min, Erik Splinter, Margit Bleijs, Marian Groot Koerkamp, Willemijn Breunis, Michael Torsten Meister, Waleed Hassan Kholossy, Frank C. P. Holstege, Jan J. Molenaar, Wendy W. J. de Leng, Janine Stutterheim, C. Ellen van der Schoot, Godelieve A. M. Tytgat
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundLiquid biopsies combine minimally invasive sample collection with sensitive detection of residual disease. Pediatric malignancies harbor tumor-driving copy number alterations or fusion genes, rather than recurrent point mutations. These reg
Externí odkaz:
https://doaj.org/article/7b442cccd01346f9baef8bf01b4fb357
Autor:
Bernarda Kazanowska, Marc Münter, Thekla von Kalle, Ewa Koscielniak, Stefan S. Bielack, Michael Torsten Meister, Gustaf Ljungman, Cooperative Weichteilsarkom Studiengruppe, Christian Vokuhl, Ruth Ladenstein, Monika Scheer, Sabine Stegmaier, Erika Hallmen, Thomas Klingebiel, Jörg Fuchs, Felix Niggli
Publikováno v:
Journal of Surgical Oncology. 122:1337-1347
BACKGROUND AND OBJECTIVES Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas that present as large, invasive tumors. Our aim was to assess outcomes, identify prognostic factors, and analyze treatment strategies in a
Autor:
Donat Kögel, Cathinka Boedicker, Michael Torsten Meister, Benedikt Linder, Thomas Klingebiel, Simone Fulda
Publikováno v:
Cancer Letters. 465:1-11
In the present study, we show that concomitant inhibition of Hedgehog (HH) signaling by the glioma-associated oncogene homolog1 (GLI1)-targeting agent GANT61 and the antiapoptotic BCL-2 protein family member MCL-1 by A-1210477 synergistically induces
Autor:
Eva Rettinger, Peter Bader, Jan Sörensen, Michael Merker, Annekathrin Heinze, Michael Torsten Meister, Andrea Jarisch, Claudia Cappel, Melanie Bremm, Thomas Klingebiel, Sabine Huenecke
Publikováno v:
Oncotarget
Prognosis of refractory childhood cancers despite multimodal treatment strategies remains poor. Here, we report a single center experience encountered in 18 patients with refractory solid malignancies treated with adoptive cellular immunotherapy (ACI
Publikováno v:
Cancer Letters. 429:19-28
In the present study, we show that pharmacological repression by the Hedgehog (Hh) pathway inhibitor (HPI) GANT61 induces expression of the proapoptotic protein Noxa in TP53-mutated embryonal pediatric tumor cells driven by Hh signaling (i.e. rhabdom
Autor:
Simone Fulda, Meike Vogler, Michael Torsten Meister, Sara Fatima Faqar-Uz-Zaman, Ulrike Heinicke
Publikováno v:
Cancer Letters. 412:131-142
BH3 mimetics are a promising new class of anticancer agents that inhibit antiapoptotic BCL-2 proteins. Here, we report that BH3 mimetics selectively targeting BCL-xL, BCL-2 or MCL-1 (i.e. A-1331852, ABT-199, A-1210477) act in concert with multiple ch
Autor:
Jan Soerensen, Andre Willasch, Michael Torsten Meister, Michael Merker, Peter Bader, Claudia Cappel, Emilia Salzmann-Manrique, Ewa Koscielniak, Bernhard Kremens, Andrea Jarisch, Thomas Krenn, Melanie Bremm, Thomas Klingebiel, Claudia Rossig, Eva Rettinger, Sabine Huenecke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0698429ec415592ff79778285c318ba
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85040950829
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85040950829
Autor:
Sara Fatima, Faqar-Uz-Zaman, Ulrike, Heinicke, Michael Torsten, Meister, Meike, Vogler, Simone, Fulda
Publikováno v:
Cancer letters. 412
BH3 mimetics are a promising new class of anticancer agents that inhibit antiapoptotic BCL-2 proteins. Here, we report that BH3 mimetics selectively targeting BCL-x
Publikováno v:
Pediatric Blood & Cancer. 62:2018-2020
Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus ri
Autor:
Manuela Hugle, Cathinka Boedicker, Simone Fulda, Heidi Hahn, Ulrike Graab, Michael Torsten Meister, Thomas Klingebiel
Publikováno v:
Cancer letters. 381(2)
The prognosis of metastatic or relapsed rhabdomyosarcoma (RMS) is poor, highlighting the need of new treatment options. In the present study, we evaluated the in vitro efficacy of arsenic trioxide (ATO) in RMS, a FDA-approved drug used in pediatric l